MitsubishiTanabe Pharma

May 9, 2013		IR Meeting for FY2012 Business Results[Material] [Audio]
May 8, 2013		Announcement of Financial Results for FY2012 ⇒R&D Pipeline "State of New Product Development"
April 30, 2013		Change of Directors
April 30, 2013		R&D "Clinical Trial Information"
April 3, 2013		Launch of BindRen for Treatment of Hyperphosphatemia in Germany and Austria
April 1, 2013		Transfer of Tanabe Europe’s shares
April 1, 2013		U.S. FDA Approves Canagliflozin (TA-7284) for the Treatment of Adult Patients with Type 2 Diabetes
March 21, 2013		R&D "Clinical Trial Information"
February 28, 2013		Approval for time-window extension of the thrombolytic agents GRTPA and ACTIVACIN up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular disease
February 21, 2013		Information Meeting [Material][Audio] ⇒[Q&A](March 1, 2013)
February 21, 2013		Helicobacter pylori Gastritis Approved as Additional Indication in Japan for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitor
February 1, 2013		Conference Call for FY2012 3rd Quarter Business Results [Material][Audio] ⇒[Q&A](February 8, 2013)
February 1, 2013		Announcement of FY2012 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
January 29, 2013		BindRen Granted Marketing Authorization in Europe for Treatment of Hyperphosphatemia
October 29, 2012		Conference Call for FY2012 2nd Quarter Business Results [Material][Audio] ⇒[Q&A](November 5, 2012)
October 29, 2012		Announcement of FY2012 2nd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
October 26, 2012		Launch of TETRABIK Adsorbed Diphtheria-purified Pertussis-tetanus inactivated polio (Sabin strain) Combined Vaccine
October 19, 2012		Notice Regarding Dissolution of Capital Alliance with Choseido Pharmaceutical Co., Ltd.
October 11, 2012		CSR Report 2012
October 10, 2012		Outcome of Global Phase III (EPPIC) Studies
October 1, 2012		Outsourcing of Logistics Operations
September 28, 2012		Application for time-window extension of the thrombolytic agents GRTPA and ACTIVACIN up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular disease
September 20, 2012		Launch of "Simponi”, a human TNFα monoclonal antibody in Indonesia
September 13, 2012		MAINTATE Tablets: Selective β1 Antagonist Notice regarding application for additional indication for chronic atrial fibrillation
August 31, 2012		Companies Submit Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or Metronidazole
August 31, 2012		Notice regarding dissolution of Bipha Corporation-related joint venture with Nipro Corporation
August 28, 2012		Launch of TENELIA 20mg Tablets A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan
August 21, 2012		Annual Report 2012
July 31, 2012		Conference Call for FY2012 1st Quarter Business Results [Material][Audio] ⇒[Q&A](July 31, 2012)
July 31, 2012		Announcement of FY2012 1st Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
July 23, 2012		Launch of Tranquilizer, DEPAS TABLETS 0.25 mg
July 6, 2012		Launch of Argatroban, a Selective Antithrombin Agent, in UK
June 29, 2012		Marketing and Manufacturing Approval Received for TENELIA 20mg Tablets A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan
June 22, 2012		Notice of Resolution of the 5th Ordinary General Meeting of Shareholders ⇒Results of the Exercise of Voting Rights(June 25, 2012)
June 22, 2012		IR "Financial Data"
June 6, 2012		Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Taiwan
June 1, 2012		Termination of License Agreement with Cytochroma for MT-2832 (Generic Name: Lunacalcipol) as a Treatment for Secondary Hyperparathyroidism
May 15, 2012		Notice Regarding Transfer of Fine Chemical Operations
May 14, 2012		R&D "Clinical Trial Information"
May 10, 2012		IR Meeting for FY2011 Business Results[Material] [Audio] ⇒[Q&A](May 18, 2012)
May 9, 2012		Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Indonesia
May 8, 2012		Announcement of Financial Results for FY2011 ⇒R&D Pipeline "State of New Product Development"
May 8, 2012		Notice of Dividend of Retained Earnings
May 8, 2012		New Organization in Plasma Fractionation Operations Establishment of “Japan Blood Products Organization”
May 8, 2012		Remicade for I.V. Infusion 100, Anti-Human TNF α Monoclonal Antibody A New Option to Shorten Infusion Time
May 8, 2012		Remicade for I.V. Infusion 100, Anti-Human TNF α Monoclonal Antibody Lifting of Condition on Approval for Psoriasis
May 7, 2012		VIVUS gains NDA approval for TA-1790 in the US
March 29, 2012		Launch of "SIMPONI”, a human TNFα monoclonal antibody in Taiwan
March 21, 2012		“IMUSERA Capsules 0.5mg” Multiple Sclerosis Treatment AgentNotice regarding revision of “warnings” and “important basic precautions” sections of prescribing information
March 7, 2012		Conclusion of Research Collaboration Agreement for Next-Generation Vaccines
March 6, 2012		Daiichi Sankyo and Mitsubishi Tanabe Pharma Establish Strategic Alliance to Contribute to the Treatment of Diabetes in Japan Companies conclude joint sales agreement for two treatments for type 2 diabetes mellitus - MP-513 and TA-7284
January 31, 2012		Conference Call for FY2011 3rd Quarter Business Results [Material][Audio] ⇒[Q&A](February 6, 2012)
January 31, 2012		Announcement of FY2011 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
January 16, 2012		Conclusion of Licensing Agreement for Hib Vaccine
December 1, 2011		Dainippon Sumitomo Pharma and Yoshitomiyakuhin terminate co-promotion of antipsychotics, LONASEN and LULLAN
November 25, 2011		Launch of "IMUSERA Capsules 0.5mg"Japan's First Oral Dosing Multiple Sclerosis Treatment with Novel Mode of Action
November 25, 2011		Launch of Antiviral Agent "TELAVIC Tablets 250 mg"Novel Mode of Action for Chronic Hepatitis C Treatment
November 25, 2011		Approval of Additional Indication for MODIODAL Tablets 100 mg a Sleep Disorder Treatment
November 21, 2011		CSR Report 2011
November 18, 2011		Notice of postponement of integrating the plasma fractionation operations of the Japanese Red Cross Society and Mitsubishi Tanabe Pharma Corporation
October 31, 2011		Conference Call for FY2011 2nd Quarter Business Results [Material][Audio] [Q&A](November 7, 2011)
October 31, 2011		Announcement of FY2011 2nd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
October 31, 2011		Revision of Dividend of Retained Earnings and Year-end Dividend Forecast
October 21, 2011		Toray, Mitsubishi Tanabe Pharma Reach North American License Agreement on Antipruritic Agent, TRK-820
October 19, 2011		IR Meeting for Medium-Term Management Plan[Material][Audio] [Q&A](October 28, 2011)
October 17, 2011		Formulation of Medium-Term Management Plan 11-15 New Value Creation ＜Presentation Material＞
September 26, 2011		Approval for "IMUSERA Capsules 0.5mg" Japan's First Once-Daily Oral Dosing Multiple Sclerosis Treatment
September 26, 2011		Approval for TELAVIC 250mg Tablet Novel Mode of Action for Chronic Hepatitis C Treatment
September 26, 2011		Approval for Additional Indication of Generalized Myasthenia GravisVenoglobulinIH 5% for Intravenous Injection,a Human Immunoglobulin Preparation Derived from Donated Plasma
September 22, 2011		Presentation Material for Deutsche Securities Japan Pharmaceutical Conference 2011
September 15, 2011		Launch of "SIMPONI (golimumab) Subcutaneous Injection 50mg Syringe" A Treatment of Rheumatoid Arthritis
September 1, 2011		New Drug Application Filed in Japan for MP-513 a Type 2 Diabetes Treatment
August 31, 2011		Annual Report 2011
August 31, 2011		R&D "Clinical Trial Information"
August 22, 2011		Mitsubishi Tanabe Pharma Prevails in U.S. Argatroban Patent Litigation
August 17, 2011		Remicade for I.V. Infusion 100, Anti-Human TNF α Monoclonal-Antibody Approval for a Partial Change of Dosage and Usage in Crohn’s Disease
August 17, 2011		R&D "Clinical Trial Information"
August 4, 2011		Conference Call for FY2011 1st Quarter Business Results [Q&A〕
July 29, 2011		Conference Call for FY2011 1st Quarter Business Results [Material〕[Audio]
July 29, 2011		Announcement of FY2011 1st Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
July 29, 2011		Revision to First Half and Full Year Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2012
July 21, 2011		The NHI Drug Price Listing and Launch of an Anti-depressant, Lexapro 10mg
July 19, 2011		Notice Regarding a Business Suspension Order for the Ashikaga Plant of Mitsubishi Tanabe Pharma Factory Ltd. and a Business Improvement Order for Mitsubishi Tanabe Pharma Corporation
July 1, 2011		Approval for "SIMPONI Subcutaneous Injection 50mg Syringe(Generic Name: Golimumab)" for Treatment of Rheumatoid Arthritis
June 22, 2011		Notice of Resolution of the 4th Ordinary General Meeting of Shareholders
June 17, 2011		Notice of a basic agreement between the Japanese Red Cross Society and Mitsubishi Tanabe Pharma Corporation regarding the commencement of discussions about the integration of their plasma fractionation operations
June 2, 2011		AZANIN Tablets 50mg, Immunosuppressant Approval for Additional Indication for Refractory Rheumatic Diseases
May 27, 2011		Launch of Anti-allergy Agent, Bepotastine Besilate in China and Indonesia
May 20, 2011		Approval for Additional Indication for selective β1 antagonist, MAINTATE Tablets 0.625, 2.5, and 5 and Launch of MAINTATE Tablets 0.625
May 20, 2011		Approval for Additional Indications for the Selective Antithrombin Agents,Novastan HI Injection 10 mg/2mL and Slonnon HI Injection 10 mg/2mL
May 20, 2011		Approval for Additional Indication of Anti-D Human Immunoglobulin I.M.1000-BENESIS (Dry anti-Rho(D) Immune Human Globulin)
May 19, 2011		IR Meeting for FY2010 Business Results [Q&A〕
May 12, 2011		IR Meeting for FY2010 Business Results[Material] [Audio]
May 10, 2011		Announcement of Financial Results for FY2010 ⇒R&D Pipeline "State of New Product Development"
May 10, 2011		Partial Amendment of the Articles of Incorporation
April 27, 2011		Change of Directors, and Organization
April 27, 2011		Summary of the Quality Control Incident
April 11, 2011		Impact of the Great East Japan Earthquake (3rd Notice)
March 30, 2011		Impact of the 2011 off the Pacific coast of Tohoku Earthquake (2nd Notice)
March 28, 2011		Novartis receives European Commission approval for FTY720, the first oral multiple sclerosis treatment for use in the EU
March 15, 2011		Impact of the 2011 off the Pacific coast of Tohoku Earthquake
March 14, 2011		Mitsubishi Tanabe Pharma Supports Japan Earthquake Relief Efforts ⇒Mitsubishi Chemical Holdings Group：Aid for Areas Affected
March 11, 2011		Open innovation laboratory for drug discovery and development by Mitsubishi Tanabe Pharma and Kyoto University -Basic and clinical research project for CKD drugs-
March 7, 2011		Transfer of Marketing Rights of 5 Long-term Listed Drugs to Tanabe Seiyaku Hanbai
January 28, 2011		Application Submitted in Japan for MP-424 a Novel Chronic Hepatitis C Treatment
January 28, 2011		Nycomed and Mitsubishi Tanabe Pharma to Terminate Collaborative Development of APTA-2217, Roflumilast for Treatment of Respiratory Diseases in Japanese Market
January 26, 2011		Notice Regarding Voluntary Recall of Three Drugs (Six Dosage Sizes)
January 11, 2011		"Kremezin", Drug for Chronic Renal Failure Transfer of Marketing Rights in Japan
December 21, 2010		Out-Licensing of Bepotastine Besilate for Ophthalmic Use to a South Korea
December 20, 2010		Application Submitted in Japan for FTY720, a Novel Multiple Sclerosis Treatment
December 14, 2010		Commencement of R&D Partnership with Anaphore for Atrimer Technology (Novel Trivalent Proteins)
December 9, 2010		R&D Meeting [Q&A]
December 1, 2010		Removal of Grace Period
December 1, 2010		R&D Meeting[Material] [Audio]
October 29, 2010		Notice Regarding Change in the Number of Shares Constituting One Trading Unit and Partial Amendments to the Articles of Incorporation
September 28, 2010		Novartis gains NDA approval for FTY720 in the US
June 16, 2010		Notice Regarding Submission of Business Improvement Plans
April 13, 2010		Notice Regarding Administrative Action Related to Violation of Pharmaceutical Affairs Law
January 7, 2010		Conclusion of Co-marketing Agreement for an Anti-Depressant, Escitalopram in Japan
December 21, 2009		Name Change of Pharmaceutical Manufacturing & Sales Subsidiaryin Korea (Welfide Korea Co., Ltd.)
October 13, 2009		Establishment of Pharmaceutical Sales & Marketing Company and Reorganization of Group Companies in the U.S.
April 10, 2009		Standard for our company’s payment burdens related to fees required for benefit payments and other operations, based on “the Special Relief Law Concerning the Payment of Benefits to Relieve the Patients of Hepatitis C (abbreviated title)”
March 24, 2009		Withdrawal of Marketing Authorization for Recombinant Human Serum Albumin Preparation “Medway Injection 5%” and Voluntary Recall of “Medway Injection 5%” and “Medway Injection 25%”
September 19, 2008		The Basic Agreement to Be Concluded with the National Plaintiffs Group on the HCV Class Action
May 7, 2008		Announcement of Corporate Behavior Charter and Medium-Term Management Plan
October 1, 2007		Announcement of the Establishment of Mitsubishi Tanabe Pharma Corporation